RespireRx Pharmaceuticals Inc (fka RSPI)

[moosedogger]

Why did you change your mind? At $3+ to $5 or so, a financing makes more sense, but at $2 it seems like another giveaway to Rodman.

Last October you said:

>>STOLL- Take on debt in lieu of dilution...

Yes, debt is risky for developing stage companies, but not in this case..COR should obtain $20-30 million mid-term loan and pay it off with Big Pharma upfront proceeds and/or equity purchase at much higher prices or wait to do a secondary at higher prices after the Big Pharma deal is concluded. The loan proceeds would give COR the strength from which to negotiate a better deal with the pharma companies.

In no way should COR issue a secondary offer prior to the Big Pharma deal...that would be very unwise.<<

http://investorshub.advfn.com/boards/read_msg.asp?message_id=13884882